Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Brisbane, 4111, Australia; Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, Brisbane, 4029, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, 4111, Australia; School of Nursing, Queensland University of Technology, Brisbane, 4059, Australia.
Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Brisbane, 4111, Australia; Nursing and Midwifery Research Centre, Royal Brisbane and Women's Hospital, Brisbane, 4029, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, 4111, Australia.
Infect Dis Health. 2021 Aug;26(3):182-188. doi: 10.1016/j.idh.2021.03.001. Epub 2021 Mar 29.
Peripheral intravenous catheters (PIVCs) are medical devices used to administer intravenous therapy but can be complicated by soft tissue or bloodstream infection. Monitoring PIVC safety and quality through clinical auditing supports quality infection prevention however is labour intensive. We sought to determine the optimal patient 'number' for clinical audits to inform evidence-based surveillance.
We studied a dataset of cross-sectional PIVC clinical audits collected over five years (2015-2019) in a large Australian metropolitan hospital. Audits included adult medical, surgical, women's, cancer, emergency and critical care patients, with audit sizes of 69-220 PIVCs. The primary outcome was PIVC complications for one or more patient reported symptom/auditor observed sign of infection or other complications. Complication prevalence and 95% confidence interval (CI) were calculated. We modelled scenarios of low (10%), medium (20%) and high (50%) prevalence estimates against audit sizes of 20, 50, 100, 150, 200, 250, and 300. This was used to develop a decision-making tool to guide audit size.
Of 2274 PIVCs evaluated, 475 (21%) had a complication. Complication prevalence per round varied from 7.8% (95% CI, 4.2-12.9) to 39% (95% CI, 32.0-46.4). Precision improved with larger audit size and lower complication rates. However, precision was not meaningfully improved by auditing >150 patients at a complication rate of 20% (95% CI 13.9%-27.3%), nor >200 patients at a complication rate of 50% (95% CI 42.9%-57.1%).
Audit sizes should be 100 to 250 PIVCs per audit round depending on complication prevalence.
外周静脉导管(PIVC)是用于静脉治疗的医疗器械,但可能会导致软组织或血流感染。通过临床审核监测 PIVC 的安全性和质量有助于预防感染,但这是一项劳动密集型工作。我们试图确定最佳的患者数量进行临床审核,以提供基于证据的监测。
我们研究了在澳大利亚一家大型都市医院进行的为期五年(2015-2019 年)的横断面 PIVC 临床审核数据集。审核包括成年内科、外科、妇科、癌症、急诊和重症监护患者,审核大小为 69-220 个 PIVC。主要结果是一个或多个患者报告的症状/审核员观察到的感染或其他并发症的 PIVC 并发症。计算了并发症的患病率和 95%置信区间(CI)。我们针对低(10%)、中(20%)和高(50%)患病率估计值,对 20、50、100、150、200、250 和 300 个审核大小进行了建模。这用于开发一个决策工具来指导审核大小。
在评估的 2274 个 PIVC 中,有 475 个(21%)发生了并发症。每轮审核的并发症患病率从 7.8%(95%CI,4.2-12.9)到 39%(95%CI,32.0-46.4)不等。随着审核大小的增加和并发症率的降低,准确性得到提高。然而,当并发症率为 20%(95%CI 13.9%-27.3%)时,审核>150 名患者,或者当并发症率为 50%(95%CI 42.9%-57.1%)时,审核>200 名患者,准确性不会有明显提高。
根据并发症的患病率,每次审核应包含 100 至 250 个 PIVC。